Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate. The STIMULUS-MDS2 trial was ...

Now, with a pair of phase 3 trials for oral BTK inhibitor remibrutinib meeting their objectives, the Swiss pharma group is on course to file for approval of the drug, potentially ending a decade ...